$AFFY News
Last published 2y ago
- 2y agoAFFYBEAMDASHLYFT+32024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and SpeakersBusiness WireThe Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston. The Summit is the largest undergraduate
- 5y agoAFFYBOLTETNBPBAXU+389bio Announces Appointment of Kathy LaPorte to its Board of DirectorsGlobeNewswireSAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, to
- 13y agoAFFYAffymax Reports Fourth Quarter and Year-End 2012 Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the fourth quarter and year ended December 31, 2012. The net loss for the fourth quarter of 2012 was $68.3 million (or ($1.85) per share) compared to a net loss of $29.4 million (or ($0.82) per share) for the fourth quarter of 2011.
- 13y agoAFFYAffymax Announces Reduction in Force to Align Resources Around Ongoing Product InvestigationBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that it will reduce its workforce as part of a plan to focus the company’s resources on the ongoing investigation of reported hypersensitivity reactions in patients receiving OMONTYS® (peginesatide) Injection following the nationwide voluntary recall of product from the market. This action will reduce the company’s wo ...
- 13y agoAFFYLawyers Seek to Restore Investors' Losses and Confidence in Affymax, Announces Deans & Lyons Law Firm LLPBusiness WireDALLAS--(BUSINESS WIRE)--Deans & Lyons LLP securities lawyers announced potential claims on behalf of shareholders of Affymax (NASDAQ: AFFY) who purchased or acquired stock from December 8, 2011 until February 22, 2013. Concerned AFFY investors with stock losses are encouraged to contact attorney Hamilton Lindley at 877-819-8033 or hlindley@deanslyons.com about their rights and remedies.
- 13y agoPANWAFFYGRPNU.S. Stock-Index Futures Drop as Spending Cuts LoomBloombergU.S. stock-index futures declined as investors braced for automatic cuts in federal spending due to take effect tonight, while awaiting data on manufacturing and consumer spending.
- 13y agoAFFYFinkelstein Thompson LLP Announces Investigation Of Affymax, Inc.Business WireWASHINGTON--(BUSINESS WIRE)--The law firm Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Affymax, Inc. (“Affymax” or “the Company”) (Nasdaq: AFFY). Finkelstein Thompson’s investigation relates to the recent announcement by Affymax and partner Takeda Pharmaceutical that they were voluntarily recalling all lots of Omontys, Affymax’s flagship anemia drug.
- 13y agoAFFYGlancy Binkow & Goldberg LLP Announces Investigation of Affymax, Inc.Business WireLOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of purchasers of the securities of Affymax, Inc. (“Affymax” or the “Company”) (NASDAQ:AFFY) concerning possible violations of federal securities laws. The investigation focuses on allegations that certain statements issued by Affymax were false and misleading regarding the Compa ...
- 13y agoAFFYShareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Affymax, Inc.Business WireSAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether Affymax, Inc. (Nasdaq: AFFY) violated state or federal laws when communicating serious side effects and the subsequent voluntary recall of its anemia drug, Omontys, in February 2013.
- 13y agoAFFYAffymax Announces Teleconference and WebcastBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) will host a teleconference and webcast at 5:30 a.m. Pacific Time; 8:30 a.m. Eastern Time today, February 25, to discuss the voluntary recall of OMONTYS® (peginesatide) Injection. Interested parties can listen to the live teleconference by dialing (866) 393-1565 from the U.S. or +1(973) 409-9608 for international callers. Individuals ...
- 13y agoAFFYAffymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) InjectionBusiness WirePALO ALTO, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited (Takeda) today have decided to voluntarily recall all lots of OMONTYS® (peginesatide) Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal. The companies ...
- 13y agoAFFYAffymax to Present at the BIO CEO & Investor ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that John Orwin, the company's chief executive officer, will present at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) in New York City.
- 13y agoAFFYAffymax Announces Updates to Senior Leadership TeamBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced the promotion of Christine Conroy, Pharm.D., to senior vice president, Regulatory Affairs and Quality Assurance, as well as Tim Varacek to vice president, Sales and Account Management. The company also announced Robert F. Venteicher, Ph.D., will retire as Affymax’s senior vice president, technical operations effective ...
- 13y agoAFFYNew England Journal of Medicine Publishes Pivotal Trial Data for OMONTYS® (peginesatide) Injection for Treatment of Anemia in Adult Chronic Kidney Disease Patients on HemodialysisBusiness WirePALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced that pivotal Phase 3 data on the safety and efficacy of OMONTYS® (peginesatide) Injection were published in the January 24th issue the New England Journal of Medicine (NEJM). These studies, known as EMERALD 1 and 2, compared OMONTYS given once monthly to ...
- 13y agoAFFYTakeda and Affymax Announce Supply Agreement for OMONTYS® (Peginesatide) Injection with DSI RenalBusiness WireDEERFIELD, Ill. & PALO ALTO, Calif.--(BUSINESS WIRE)--Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) and Affymax, Inc. (Nasdaq: AFFY) today announced that Takeda Pharmaceuticals America, Inc. (TPA) has entered into a supply agreement for sourcing and supply of OMONTYS® (peginesatide) Injection with DSI Renal, one of the largest dialysis providers in the United States (U.S.). OMONTYS is the only once- ...
- 13y agoAFFYAffymax to Present at the J.P. Morgan Healthcare ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that John Orwin, the company's chief executive officer, will present at the 31st Annual J.P. Morgan Healthcare Conference on Thursday, January 10, 2013 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time) in San Francisco.
- 13y agoAFFYAffymax and Takeda Announce Permanent J-Code for OMONTYS® (peginesatide) Injection is in EffectBusiness WirePALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced that the J-code assigned by the Centers for Medicare and Medicaid Services (CMS) for OMONTYS® (peginesatide) Injection is now effective. This permanent OMONTYS-specific billing code, J0890, will continue to provide for streamlined reimbursement for dialy ...
- 13y agoAFFYAffymax Announces Upcoming Webcasts and Conference ParticipationBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced the company’s participation in the following investors conferences.
- 14y agoAFFYAffymax to Present at the Lazard Capital Markets Healthcare ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that John Orwin, the company's chief executive officer, will present at the Lazard Capital Markets 9TH Annual Healthcare Conference on Wednesday, November 14, 2012 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time) in New York City.
- 14y agoAFFYAffymax Reports Third Quarter 2012 Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (NASDAQ: AFFY) today reported financial results for the third quarter ended September 30, 2012. The net loss for the third quarter of 2012 was $24.6 million (or ($0.68) per share) compared to a net loss of $9.8 million (or ($0.28) per share) for the third quarter of 2011.
- 14y agoAFFYAffymax and Takeda Announce Analyses from OMONTYS® (peginesatide) Injection Phase 3 Dialysis Studies Presented at 2012 American Society of Nephrology MeetingBusiness WirePALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated OMONTYS® (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis ...
- 14y agoAFFYAffymax Announces Third Quarter 2012 Financial Results Teleconference and WebcastBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that it will host a teleconference and webcast with management to provide a general business overview, as well as to discuss its third quarter 2012 financial results on Thursday, November 8, 2012 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Financial results for the quarter ended September 30, 2012 will be rele ...
- 14y agoAFFYAffymax and Takeda Announce OMONTYS® Data Presentations at the American Society of Nephrology Kidney Week 2012Business WirePALO ALTO, Calif., & DEERFIELD, Ill.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA), today announced that multiple abstracts on OMONTYS® (peginesatide) Injection have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2012 taking place October 30 – November 4, 2012 in San Diego, Calif.
- 14y agoAFFYAffymax Appoints Karin L. Walker as Vice President of Finance and Chief Accounting OfficerBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that it has appointed Karin L. Walker, CPA, as vice president of finance and chief accounting officer. Ms. Walker has over two decades of financial management experience, including in the biotechnology and pharmaceutical industries. In this newly created position, Ms. Walker will report to Herb Cross, Affymax’s chief ...
- 14y agoAFFYAffymax to Present at the UBS 2012 Global Life Sciences ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that John Orwin, the company's chief executive officer, will present at the UBS 2012 Global Life Sciences Conference on Wednesday, September 19, 2012 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) in New York City.
- 14y agoAFFYAffymax Announces Upcoming Webcasts and Conference ParticipationBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (NASDAQ: AFFY) today announced the company's participation in the following investor conferences next week.
- 14y agoAFFYAffymax Announces Upcoming Webcasts and Conference ParticipationBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced the company's participation in the following investor conferences next week.
- 14y agoAFFYAffymax Reports Second Quarter 2012 Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the second quarter ended June 30, 2012. The net loss for the second quarter of 2012 was $32.0 million (or ($0.89) per share) compared to a net loss of $12.5 million (or ($0.35) per share) for the second quarter of 2011.
- 14y agoAFFYTakeda and Affymax Announce Supply Agreement for OMONTYS® (peginesatide) Injection with U.S. Renal Care, Inc.Business WireDEERFIELD, Ill. & PALO ALTO, Calif.--(BUSINESS WIRE)--Takeda Pharmaceuticals U.S.A. (TPUSA) and Affymax, Inc. (Nasdaq:AFFY) today announced that Takeda Pharmaceuticals America, Inc. (TPA) has entered into a supply agreement for sourcing and supply of OMONTYS® (peginesatide) Injection with U.S. Renal Care, Inc. and certain of its affiliates, representing one of the top 10 dialysis providers in the ...
- 14y agoAFFYAffymax Announces Second Quarter 2012 Financial Results Teleconference and WebcastBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that it will host a teleconference and webcast with management to provide a general business overview, as well as to discuss its second quarter 2012 financial results on Wednesday, August 8, 2012, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Financial results for the quarter ended June 30, 2012 will be released ...
- 14y agoAFFYTakeda and Affymax Announce Supply Agreement for OMONTYS® (peginesatide) Injection with Fresenius Medical Care North AmericaBusiness WireDEERFIELD, Ill. & PALO ALTO, Calif.--(BUSINESS WIRE)--Takeda Pharmaceuticals U.S.A. (TPUSA) and Affymax, Inc. (Nasdaq:AFFY) today announced that Takeda Pharmaceuticals America, Inc. (TPA) has entered into a supply agreement for sourcing and supply of OMONTYS® (peginesatide) Injection to Fresenius Medical Care North America and certain of its affiliates. OMONTYS is the only once-monthly erythropoie ...
- 14y agoAFFYAffymax Promotes Michael Holfinger, Ph.D., to Vice President, Manufacturing and CMC DevelopmentBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced the promotion of Michael Holfinger, Ph.D., to vice president, manufacturing and CMC development. Dr. Holfinger, who has more than two decades of experience in global manufacturing services for pharmaceutical and biotechnology companies, joined Affymax in 2006 as director, process development and manufacturing.
- 14y agoAFFYAffymax to Present at the Jefferies 2012 Global Healthcare ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that John Orwin, the company's chief executive officer, will present at the Jefferies 2012 Global Healthcare Conference on Thursday, June 7, 2012 at 1:30 p.m. Eastern Time in New York City.
- 14y agoWYNNAMZNLOPEFN+2Electronic Arts, Mako Surgical, Vivus, Wynn: U.S. Equity PreviewBloombergShares of the following companies may have unusual moves in U.S. trading tomorrow. Stock symbols are in parentheses, and prices are as of 4:39 p.m. in New York.
- 14y agoAFFYAffymax Reports First Quarter 2012 Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the first quarter ended March 31, 2012. The net income for the first quarter of 2012 was $31.5 million (or $0.87 per share) compared to a net loss of $9.6 million (or $(0.36) per share) for the first quarter of 2011.
- 14y agoAFFYAffymax Announces Upcoming Webcasts and Conference ParticipationBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today announced the company's participation in the following investor conferences during the month of May.
- 14y agoAFFYAffymax Announces First Quarter 2012 Financial Results Teleconference and WebcastBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that it will host a teleconference and webcast with management to provide a general business overview, as well as to discuss its first quarter 2012 financial results on Monday, May 7, 2012, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Financial results for the quarter ended March 31, 2012 will be released after ...
- 14y agoAFFYOMONTYS® (Peginesatide) Injection Now Available for Adult Chronic Kidney Disease (CKD) Patients on Dialysis in the United StatesBusiness WirePALO ALTO, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Affymax, Inc. (NASDAQ:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that OMONTYS® (peginesatide) Injection is now available only for use in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to ...
- 14y agoAFFYAffymax and Takeda Announce Centers for Medicare and Medicaid Services Has Assigned a Q-Code for OMONTYS® (Peginesatide) InjectionBusiness WirePALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals U.S.A. (TPUSA) today announced that the Centers for Medicare and Medicaid Services (CMS) has granted a unique product reimbursement code, or Q-code, for OMONTYS® (peginesatide) Injection. The OMONTYS-specific billing code, Q2047, will help streamline the billing process for dialysis organiz ...
- 14y agoAFFYAffymax Receives a $50 Million Milestone Payment for U.S. Approval of OMONTYS® (peginesatide) InjectionBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that it has received a $50 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize OMONTYS® (peginesatide) Injection. The milestone was triggered by the U.S. Food and Drug Administration (FDA) approval of OMONTYS on Marc ...
- 14y agoAFFYAffymax and Takeda Announce FDA Approval of OMONTYS® (Peginesatide) Injection for the Treatment of Anemia Due to Chronic Kidney Disease (CKD) in Adult Patients on DialysisBusiness WirePALO ALTO, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the U.S. Food and Drug Administration (FDA) approved OMONTYS® (peginesatide) Injection for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. OMONTYS is the only once-monthly erythropoiesis-stimulating agen ...
- 14y agoAFFYAffymax® Reports Year End 2011 Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the year ended December 31, 2011. The net loss for the year ended December 31, 2011 was $61.4 million compared to a net loss of $14.1 million for the year ended December 31, 2010.
- 14y agoAFFYAffymax Announces Yearend 2011 Financial Results Teleconference and WebcastBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that it will host its first financial results teleconference and webcast with management to provide a general business overview, as well as to discuss full year 2011 financial results, on Wednesday, March 14, 2012, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Financial results for the year ended December 31, 20 ...
- 14y agoAFFYAffymax to Receive $5 Million Milestone Payment for Acceptance of European Marketing Authorization Application for PeginesatideBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that it will receive a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide. The milestone is triggered by the European Medicines Agency (EMA) acceptance of the Marketing Authorization Application (MAA ...
- 14y agoAFFYAffymax Announces Upcoming Webcasts and Conference ParticipationBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today announced the company’s participation at the following investor conferences over the next several weeks.
- 14y agoAFFYAffymax to Present at 14th Annual BIO CEO & Investor ConferenceBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that John Orwin, the company’s chief executive officer, will present at the 14th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2012 at 3:00 p.m. Eastern Time in New York City.
- 14y agoAFFYAffymax Promotes Cynthia Smith to Vice President, Market Access and Commercial DevelopmentBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced the promotion of Cynthia Smith to vice president, market access and commercial development. Ms. Smith, who has 15 years of experience in healthcare market access strategies, joined Affymax in October 2008 as executive director, public policy, payer strategy, and operations.
- 14y agoAFFYAffymax to Webcast Analyst Briefing EventBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that it will webcast an analyst briefing on Tuesday, January 10 at 7:15 a.m. PT. During the event, Affymax management will provide a general business update including a discussion of the peginesatide development program.
- 14y agoAFFYTakeda and Affymax Provide Update on Peginesatide Commercialization Rights in JapanBusiness WireOSAKA, Japan & PALO ALTO, Calif.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) and Affymax, Inc. (Nasdaq:AFFY) today announced that Takeda has decided not to commercialize peginesatide in Japan. Peginesatide is an investigational therapy for use in the treatment of patients with anemia due to chronic kidney disease (CKD). Takeda and Affymax will explore other options for the c ...
- 14y agoAFFYFDA Advisory Committee Voted in Favor of Benefit/Risk Profile for Peginesatide for Treatment of Anemia in Chronic Kidney Disease Patients on DialysisBusiness WireSILVER SPRING, Md. & OSAKA, Japan--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due ...